FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315703425> ?p ?o ?g. }

• W4315703425 endingPage "e45" @default.
• W4315703425 startingPage "e45" @default.
• W4315703425 abstract "Objective: To investigate the effect of esaxerenone on home blood pressure (BP) and albuminuria in Japanese hypertensive patients with diabetic kidney disease (DKD) who had an inadequate response to BP-lowering treatment with a renin angiotensin system (RAS) inhibitor or a RAS inhibitor plus a calcium channel blocker (CCB). Design and method: The EX-DKD study (jRCTs061190027) was a multicenter, open-label study conducted in Japan. The study enrolled hypertensive patients with DKD who had previously received a RAS inhibitor or a RAS inhibitor plus CCB for < 12 weeks, and had sitting office systolic BP (SBP) 130 to < 180 mmHg and/or diastolic BP (DBP) 80 to < 110 mmHg, UACR < 1000 mg/g creatinine, and eGFRcreat 30 to < 60 mL/min/1.73m2 at baseline. Based on baseline UACR, the patients were divided into 3 subcohorts: UACR < 30, 30 to < 300, and 300 to < 1000 mg/g creatinine. Esaxerenone was incrementally dosed for 12 weeks: 1.25, 2.5, and 5 mg/day at the start of treatment, Week4, and Week8, respectively, based on each patient's condition. The primary efficacy endpoint was change in morning home SBP/DBP from baseline to end of treatment (EOT). Secondary endpoints included the proportion of patients achieving target BP at Week12, change in UACR from baseline to EOT, and safety (including serum potassium level). Results: The baseline characteristics of the overall study population (n = 109) were mean age, 72.6 years; male, 54.1%; morning home SBP/DBP, 135.6/75.9 mmHg; UACR < 30, 30 to < 300, and 300 to < 1000 mg/g creatinine, 41.3%, 37.6%, and 21.1%, respectively; eGFRcreat, 49.4 mL/min/1.73m2; RAS inhibitor, 33.0%; RAS inhibitor plus CCB, 67.0%. Morning home SBP/DBP decreased significantly from baseline to EOT in the total population (-11.6/-5.2 mmHg, both p < 0.001) and all UACR subcohorts (all p < 0.001). Similar results were obtained for bedtime home and office BP. At Week12, 38.5% of the total population had achieved target morning home BP. UACR improved significantly from baseline to EOT in the total population and UACR subcohorts; the overall percentage change was -50.9% (p < 0.001). Incidences of treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 23.2% and 7.1%, respectively. The percentage of patients with serum potassium <5.5 mEq/L during the study period was 2.7%, and no patients had serum potassium < 6.0 mEq/L. Conclusions: Esaxerenone significantly reduced morning home BP as well as bedtime home and office BP and significantly halved albuminuria in Japanese hypertensive patients with DKD. The effects were consistent regardless of their UACR severity without clinically relevant serum potassium elevation." @default.
• W4315703425 created "2023-01-12" @default.
• W4315703425 creator A5004599472 @default.
• W4315703425 creator A5007276836 @default.
• W4315703425 creator A5017606022 @default.
• W4315703425 creator A5030849831 @default.
• W4315703425 creator A5044277979 @default.
• W4315703425 creator A5045670455 @default.
• W4315703425 creator A5059157227 @default.
• W4315703425 creator A5069272303 @default.
• W4315703425 creator A5069883177 @default.
• W4315703425 creator A5074659798 @default.
• W4315703425 creator A5081993494 @default.
• W4315703425 creator A5087320347 @default.
• W4315703425 creator A5091286653 @default.
• W4315703425 date "2023-01-01" @default.
• W4315703425 modified "2023-10-02" @default.
• W4315703425 title "S-17-5: EFFECT OF MINERALOCORTICOID RECEPTOR BLOCKER, ESAXERENONE, ON HOME BLOOD PRESSURE AND ALBUMINURIA IN JAPANESE HYPERTENSIVE PATIENTS WITH DKD (EX-DKD STUDY)" @default.
• W4315703425 doi "https://doi.org/10.1097/01.hjh.0000913148.92173.ae" @default.
• W4315703425 hasPublicationYear "2023" @default.
• W4315703425 type Work @default.
• W4315703425 citedByCount "0" @default.
• W4315703425 crossrefType "journal-article" @default.
• W4315703425 hasAuthorship W4315703425A5004599472 @default.
• W4315703425 hasAuthorship W4315703425A5007276836 @default.
• W4315703425 hasAuthorship W4315703425A5017606022 @default.
• W4315703425 hasAuthorship W4315703425A5030849831 @default.
• W4315703425 hasAuthorship W4315703425A5044277979 @default.
• W4315703425 hasAuthorship W4315703425A5045670455 @default.
• W4315703425 hasAuthorship W4315703425A5059157227 @default.
• W4315703425 hasAuthorship W4315703425A5069272303 @default.
• W4315703425 hasAuthorship W4315703425A5069883177 @default.
• W4315703425 hasAuthorship W4315703425A5074659798 @default.
• W4315703425 hasAuthorship W4315703425A5081993494 @default.
• W4315703425 hasAuthorship W4315703425A5087320347 @default.
• W4315703425 hasAuthorship W4315703425A5091286653 @default.
• W4315703425 hasBestOaLocation W43157034251 @default.
• W4315703425 hasConcept C126322002 @default.
• W4315703425 hasConcept C126894567 @default.
• W4315703425 hasConcept C134018914 @default.
• W4315703425 hasConcept C149323552 @default.
• W4315703425 hasConcept C159641895 @default.
• W4315703425 hasConcept C164705383 @default.
• W4315703425 hasConcept C19720800 @default.
• W4315703425 hasConcept C2776174234 @default.
• W4315703425 hasConcept C2780306776 @default.
• W4315703425 hasConcept C2908647359 @default.
• W4315703425 hasConcept C71924100 @default.
• W4315703425 hasConcept C84393581 @default.
• W4315703425 hasConcept C99454951 @default.
• W4315703425 hasConceptScore W4315703425C126322002 @default.
• W4315703425 hasConceptScore W4315703425C126894567 @default.
• W4315703425 hasConceptScore W4315703425C134018914 @default.
• W4315703425 hasConceptScore W4315703425C149323552 @default.
• W4315703425 hasConceptScore W4315703425C159641895 @default.
• W4315703425 hasConceptScore W4315703425C164705383 @default.
• W4315703425 hasConceptScore W4315703425C19720800 @default.
• W4315703425 hasConceptScore W4315703425C2776174234 @default.
• W4315703425 hasConceptScore W4315703425C2780306776 @default.
• W4315703425 hasConceptScore W4315703425C2908647359 @default.
• W4315703425 hasConceptScore W4315703425C71924100 @default.
• W4315703425 hasConceptScore W4315703425C84393581 @default.
• W4315703425 hasConceptScore W4315703425C99454951 @default.
• W4315703425 hasIssue "Suppl 1" @default.
• W4315703425 hasLocation W43157034251 @default.
• W4315703425 hasLocation W43157034252 @default.
• W4315703425 hasOpenAccess W4315703425 @default.
• W4315703425 hasPrimaryLocation W43157034251 @default.
• W4315703425 hasRelatedWork W2007649676 @default.
• W4315703425 hasRelatedWork W2059593117 @default.
• W4315703425 hasRelatedWork W2092544422 @default.
• W4315703425 hasRelatedWork W2124955738 @default.
• W4315703425 hasRelatedWork W2155247768 @default.
• W4315703425 hasRelatedWork W2348373160 @default.
• W4315703425 hasRelatedWork W2356039309 @default.
• W4315703425 hasRelatedWork W2953225176 @default.
• W4315703425 hasRelatedWork W3132812123 @default.
• W4315703425 hasRelatedWork W656697013 @default.
• W4315703425 hasVolume "41" @default.
• W4315703425 isParatext "false" @default.
• W4315703425 isRetracted "false" @default.
• W4315703425 workType "article" @default.